Immune Response In-Vitro Protein RNA 
Drug Discovery World
APRIL 12, 2023
Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates. Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates.
Drug Discovery World
JANUARY 20, 2023
Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates. Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 17, 2023
Once its potential as a means of stimulating an immune response had been established, attention quickly turned to where else the technology could provide a therapeutic solution. As it stands, mRNA vaccines and therapeutics can only provide benefits if they can reach the living cells and be processed into protein.
Pharmaceutical Technology
NOVEMBER 22, 2022
billion towards the “pandemic-busting plan”, which involves the investigation of rapid response vaccine technologies. Messenger RNA vaccines contain nucleic acids that code for a specific protein, or target antigen, related to a virus or disease. Single- and multi-nation funding opportunities flooded in.
XTalks
SEPTEMBER 14, 2020
The company’s candidate vaccine, mRNA-1273, is a synthetic messenger RNA that encodes the stabilized SARS-CoV-2 spike protein. The University of Oxford/AstraZeneca partnership, in turn, is testing a viral-vectored coronavirus vaccine that again expresses the spike protein of SARS-CoV-2 virus. Moderna’s COVID-19 Vaccine.
Expert insights. Personalized for you.
52 
Let's personalize your content